Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALLR
stocks logo

ALLR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
--
--
-0.230
-97.02%
--
--
-0.230
-8%
Estimates Revision
The market is revising No Change the revenue expectations for Allarity Therapeutics, Inc. (ALLR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.12%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-41.12%
In Past 3 Month
Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.25 USD with a low forecast of 9.25 USD and a high forecast of 9.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.25 USD with a low forecast of 9.25 USD and a high forecast of 9.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.160
sliders
Low
9.25
Averages
9.25
High
9.25
Current: 1.160
sliders
Low
9.25
Averages
9.25
High
9.25
Ascendiant
NULL -> Buy
initiated
$9
2025-07-28
Reason
Ascendiant
Price Target
$9
2025-07-28
initiated
NULL -> Buy
Reason
Ascendiant initiated coverage of Allarity with a Buy rating and $9 price target. The firm sees large market opportunities for the company's DRP platform and Stenoparib drug. It believes positive clinical trial data in 2025 and 2026 will be catalysts for the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Allarity Therapeutics Inc (ALLR.O) is -1.26, compared to its 5-year average forward P/E of -0.86. For a more detailed relative valuation and DCF analysis to assess Allarity Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.86
Current PE
-1.26
Overvalued PE
0.18
Undervalued PE
-1.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.06
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.22
Undervalued EV/EBITDA
-0.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALLR News & Events

Events Timeline

(ET)
2025-12-03
09:20:00
Allarity Files $50M Mixed Securities Shelf
select
2025-11-14 (ET)
2025-11-14
09:01:00
Allarity announces Q3 earnings per share of 19 cents compared to a loss of $7.71 in the same period last year.
select
2025-09-22 (ET)
2025-09-22
08:16:04
Allarity unveils new Phase 2 clinical findings for Stenoparib
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
08-28TipRanks
3 Penny Stocks to Keep an Eye On as of August 28, 2025

  • Penny Stocks to Watch: Allarity Therapeutics, Incannex Healthcare Limited, and Firefly Neuroscience are highlighted as penny stocks to monitor on August 28, 2025, based on their Dollar Volume and market activity.

  • Allarity Therapeutics Update: The company received Fast Track designation from the FDA for its cancer treatment stenoparib, leading to a significant stock price increase of over 11% and a Dollar Volume of $553.44 million.

  • Incannex Healthcare Performance: Despite a nearly 6% drop in stock price with a Dollar Volume of $351.47 million, Incannex previously announced positive Phase 2 trial results for its psilocybin-assisted therapy, which had caused a surge of nearly 26%.

  • Firefly Neuroscience Developments: Firefly's stock fell nearly 3% with a Dollar Volume of $226.16 million after launching its new EEG technology platform, CLEAR, which enhances data quality and processing speed for brain health solutions.

[object Object]
Preview
4.5
08-27TipRanks
Tuesday's Major Stock Market Highlights: Morning News Summary!

  • Market Overview: The article highlights significant stock market stories that investors should be aware of on Tuesday.

  • TipRanks Contribution: TipRanks has compiled a list of the most relevant news and updates affecting the stock market today.

  • Investor Insights: The content aims to provide insights and information that could influence investment decisions.

  • Disclaimer: There is a disclaimer regarding the information provided, indicating it may not cover all aspects of the market.

[object Object]
Preview
4.0
08-27Benzinga
Crude Oil Prices Fall 2%; US Durable Goods Orders Decrease in July

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite up by 0.2%, while the Dow Jones dipped slightly by 0.02%. The S&P 500 also saw a minor increase of 0.10%.

  • Sector Movements: Industrial shares rose by 0.6%, whereas energy stocks experienced a decline of 0.6%.

  • Durable Goods Orders: U.S. durable goods orders fell by 2.8% in July to $302.8 billion, following a significant revised drop of 9.4% in June.

  • Global Market Trends: European and Asian markets closed lower, with notable declines in major indices such as Spain's IBEX 35 and Japan's Nikkei 225, reflecting a broader trend of decreasing stock values internationally.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Allarity Therapeutics Inc (ALLR) stock price today?

The current price of ALLR is 1.16 USD — it has increased 6.42 % in the last trading day.

arrow icon

What is Allarity Therapeutics Inc (ALLR)'s business?

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.

arrow icon

What is the price predicton of ALLR Stock?

Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.25 USD with a low forecast of 9.25 USD and a high forecast of 9.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Allarity Therapeutics Inc (ALLR)'s revenue for the last quarter?

Allarity Therapeutics Inc revenue for the last quarter amounts to -2.52M USD, decreased -3.52 % YoY.

arrow icon

What is Allarity Therapeutics Inc (ALLR)'s earnings per share (EPS) for the last quarter?

Allarity Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Allarity Therapeutics Inc (ALLR)'s fundamentals?

The market is revising No Change the revenue expectations for Allarity Therapeutics, Inc. (ALLR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.12%.
arrow icon

How many employees does Allarity Therapeutics Inc (ALLR). have?

Allarity Therapeutics Inc (ALLR) has 6 emplpoyees as of December 05 2025.

arrow icon

What is Allarity Therapeutics Inc (ALLR) market cap?

Today ALLR has the market capitalization of 18.34M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free